Clinical Commander

Back to dossier
cardio.acute-hf.peripartum-cmp.v1PRODUCTION
cardio.acute-hf.peripartum-cmp.v1

Acute HF — Peripartum cardiomyopathy (PPCM)

cardiologyacuteadult
Hard-required inputs
0 / 10
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

PPCM = HFrEF (LVEF <45%) in last month of pregnancy through 5 months postpartum, no other identifiable cause; pregnancy status drives drug selection (ACEi/ARB/warfarin teratogenic; bromocriptine adjunct)

Inputs
2
Actions
0
Advance rule
Set
Advance when

PPCM diagnosis criteria met or strong suspicion

Patient inputs (11)

Age >30 increases PPCM risk; affects future-pregnancy counseling

PPCM defined window: last month pregnancy through 5 months postpartum; trimester drives ACEi/ARB/warfarin teratogenicity decisions

Multiparity + multiple gestation + pre-eclampsia are PPCM risk factors

Cardiorenal screen + LMWH dosing + ACEi-postpartum dose adjustment

Echo LVEF <45% is the diagnostic criterion; LV chamber size + RV function + valvular assessment

NT-proBNP elevation in peripartum dyspnea is sensitive for PPCM; trends response to therapy

Rules out ischemic CMP differential; mildly elevated in PPCM but high values prompt SCAD/MI workup

PPCM is diagnosis of exclusion — must rule out pre-existing CMP, valvular, ischemic, viral myocarditis

Hemodynamic stratification — pre-eclampsia overlap common; SBP guides afterload reduction choice (hydralazine peripartum)

Hypoxemia from pulmonary edema; guides NIPPV vs intubation decision in late pregnancy

African ancestry confers 4× higher PPCM incidence and worse recovery profile

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningfulminant_cardiogenic_shock_peripartum
    Fulminant PPCM with cardiogenic shock peripartum (SBP <90, lactate ≥4, SCAI C-E) — very high maternal + fetal mortality
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningac_related_obstetric_bleeding_peripartum
    PPCM patient on therapeutic LMWH with peripartum bleeding (placental abruption, postpartum hemorrhage, intracranial hemorrhage)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevererecurrence_in_subsequent_pregnancy_with_persistent_lv_dysfunction
    Patient with prior PPCM + LVEF that did not normalize + new pregnancy — recurrence rate 30-50%, mortality up to 20%
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatebreastfeeding_compatibility_decision_in_severe_ppcm
    Severe PPCM (LVEF <35%) postpartum patient who wishes to breastfeed but bromocriptine + ARNI + SGLT2i + DOAC are not compatible with lactation
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

PPCM pregnancy-aware ADHF — substitutes hydralazine/nitrate for ACEi peripartum; adds bromocriptine postpartum per IPAC; LMWH peripartum, warfarin/DOAC postpartum
axis: ppcm_pregnancy_aware_phenotype
Selected axis "PPCM pregnancy-aware ADHF — substitutes hydralazine/nitrate for ACEi peripartum; adds bromocriptine postpartum per IPAC; LMWH peripartum, warfarin/DOAC postpartum" by default fallback (first axis)
  • furosemide
    first line
    loop_diuretic
    40 mg IV bolus then 5-10 mg/h infusion or 40-80 mg IV q6-8h • IV • as scheduled
    triggers: ppcm_with_pulmonary_edema
    DOSE PMID 21366472 high-dose IV bolus arm; safe pregnancy and lactation
    rxcui 4603
  • hydralazine
    first line
    arteriolar_vasodilator
    10-25 mg PO TID OR 5-10 mg IV q4-6h prn • PO/IV • TID
    triggers: ppcm_antepartum_afterload_reduction_needed
    Pregnancy-safe afterload reducer; substitute for ACEi/ARB during pregnancy (V-HeFT-I + ESC pregnancy 2018 PMID 30165544)
    rxcui 5470
  • isosorbide dinitrate
    first line
    venous_vasodilator_nitrate
    20-40 mg PO TID • PO • TID
    triggers: ppcm_antepartum_preload_afterload_reduction_needed
    Combine with hydralazine (A-HeFT analog) for pregnancy-safe afterload + preload reduction; ESC pregnancy 2018
    rxcui 6058
  • metoprolol succinate
    first line
    beta1_selective_blocker
    12.5-25 mg PO daily titrate • PO • daily
    triggers: ppcm_with_lvef_reduced_stable_volume
    BB safe in pregnancy and lactation; preferred BB in PPCM (CIBIS / MERIT-HF extrapolation; ACC/AHA 2022 HF Class I)
    rxcui 6918
  • carvedilol
    first line
    beta_alpha_blocker
    3.125 mg PO BID titrate • PO • BID
    triggers: ppcm_postpartum_hfref
    CAPRICORN PMID 11356436 + COPERNICUS PMID 11386262; preferred postpartum (limited lactation data but acceptable per AAP)
    rxcui 20352
  • sacubitril-valsartan
    first line
    arni
    24/26 mg PO BID titrate to 97/103 BID • PO • BID
    triggers: ppcm_postpartum_hfref_not_breastfeeding
    PIONEER-HF PMID 30403955; POSTPARTUM ONLY (TERATOGENIC — Pregnancy Category D); AAP advises against during lactation
    rxcui 1656328
  • enalapril
    first line
    acei
    2.5 mg PO BID titrate • PO • BID
    triggers: ppcm_postpartum_hfref_breastfeeding
    POSTPARTUM ONLY; enalapril and captopril are AAP-approved during lactation (low milk transfer); ACC/AHA 2022 HF
    rxcui 203123
  • spironolactone
    first line
    mra
    12.5-25 mg PO daily • PO • daily
    triggers: ppcm_postpartum_hfref_with_k_below_5
    POSTPARTUM ONLY (potential antiandrogenic teratogen); RALES PMID 10471456
    rxcui 9997
  • empagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: ppcm_postpartum_hfref_egfr_above_20_not_breastfeeding
    EMPULSE PMID 35347356; POSTPARTUM ONLY; not recommended during pregnancy or breastfeeding (animal data + limited human data)
    rxcui 1545653
  • bromocriptine
    add on
    dopamine_d2_agonist_prolactin_inhibitor
    2.5 mg PO BID × 2 weeks then 2.5 mg PO daily × 6 weeks (8 weeks total) • PO • BID then daily
    triggers: ppcm_postpartum_lvef_below_35
    IPAC RCT (Sliwa 2017 PMID 28637825): bromocriptine 8-week regimen improved LVEF recovery from 27→58% at 6 mo; POSTPARTUM ONLY (suppresses lactation); add prophylactic AC during therapy due to thrombosis risk
    rxcui 142426
  • enoxaparin
    comorbidity specific
    lmwh
    1 mg/kg SC q12h (therapeutic) OR 40 mg SC daily (prophylactic) • SC • q12h or daily
    triggers: ppcm_antepartum_with_chads2vasc_above_2_and_lvef_below_35, ppcm_postpartum_during_bromocriptine_therapy
    LMWH preferred peripartum (warfarin teratogenic 6-12 weeks gestation + fetal bleeding third trimester); ESC pregnancy 2018 PMID 30165544; therapeutic for AC indication, prophylactic during bromocriptine
    rxcui 67108
  • warfarin
    comorbidity specific
    vitamin_k_antagonist
    5 mg PO daily; INR target 2-3 • PO • daily
    triggers: ppcm_postpartum_chronic_ac_indication
    POSTPARTUM transition from LMWH; safe in lactation (no significant breast milk transfer)
    rxcui 11289
  • apixaban
    comorbidity specific
    doac_factor_xa_direct
    5 mg PO BID • PO • BID
    triggers: ppcm_postpartum_chronic_ac_not_breastfeeding
    POSTPARTUM alternative to warfarin; NOT recommended during breastfeeding (limited data); preferred for AF or LV thrombus per AHA 2022
    rxcui 1364430

outpatient playbook — drug actions (2)

  1. 1. continue 4-pillar GDMT until LVEF normalized + stable ≥6-12 mo
    rxcui 1656328
    ARNI + BB + MRA + SGLT2i at max tolerated • PO • as scheduled
    trigger: Persistent HFrEF
    ACC/AHA 2022 HF; do not de-escalate prematurely (TRED-HF PMID 30429051 — withdrawal causes deterioration)
  2. 2. consider GDMT continuation even after LVEF recovery for at least 12 months
    rxcui 1656328
    maintain • PO • as scheduled
    trigger: LVEF recovered but recent
    TRED-HF PMID 30429051; AHA 2020 PPCM scientific statement (PMID 32362133) suggests indefinite GDMT in PPCM

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: New dyspnea/orthopnea/PND in last month of pregnancy through 5 months postpartum; Echo LVEF <45% in peripartum window with no prior cardiac history (PPCM diagnostic criterion); BNP/NT-proBNP elevated in peripartum patient with dyspnea (BNP elevation NOT physiologic in pregnancy).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — Peripartum cardiomyopathy (PPCM)** (cardio.acute-hf.peripartum-cmp.v1).
Scope: PPCM = HFrEF (LVEF <45%) in last month of pregnancy through 5 months postpartum, no other identifiable cause; pregnancy status drives drug selection (ACEi/ARB/warfarin teratogenic; bromocriptine adjunct)

No severity triggers fired against current inputs.

Plan

Regimen axis: **PPCM pregnancy-aware ADHF — substitutes hydralazine/nitrate for ACEi peripartum; adds bromocriptine postpartum per IPAC; LMWH peripartum, warfarin/DOAC postpartum**.
1. furosemide 40 mg IV bolus then 5-10 mg/h infusion or 40-80 mg IV q6-8h IV as scheduled (loop_diuretic, first line) — DOSE PMID 21366472 high-dose IV bolus arm; safe pregnancy and lactation
2. hydralazine 10-25 mg PO TID OR 5-10 mg IV q4-6h prn PO/IV TID (arteriolar_vasodilator, first line) — Pregnancy-safe afterload reducer; substitute for ACEi/ARB during pregnancy (V-HeFT-I + ESC pregnancy 2018 PMID 30165544)
3. isosorbide dinitrate 20-40 mg PO TID PO TID (venous_vasodilator_nitrate, first line) — Combine with hydralazine (A-HeFT analog) for pregnancy-safe afterload + preload reduction; ESC pregnancy 2018
4. metoprolol succinate 12.5-25 mg PO daily titrate PO daily (beta1_selective_blocker, first line) — BB safe in pregnancy and lactation; preferred BB in PPCM (CIBIS / MERIT-HF extrapolation; ACC/AHA 2022 HF Class I)
5. carvedilol 3.125 mg PO BID titrate PO BID (beta_alpha_blocker, first line) — CAPRICORN PMID 11356436 + COPERNICUS PMID 11386262; preferred postpartum (limited lactation data but acceptable per AAP)
6. sacubitril-valsartan 24/26 mg PO BID titrate to 97/103 BID PO BID (arni, first line) — PIONEER-HF PMID 30403955; POSTPARTUM ONLY (TERATOGENIC — Pregnancy Category D); AAP advises against during lactation
7. enalapril 2.5 mg PO BID titrate PO BID (acei, first line) — POSTPARTUM ONLY; enalapril and captopril are AAP-approved during lactation (low milk transfer); ACC/AHA 2022 HF
8. spironolactone 12.5-25 mg PO daily PO daily (mra, first line) — POSTPARTUM ONLY (potential antiandrogenic teratogen); RALES PMID 10471456
9. empagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, first line) — EMPULSE PMID 35347356; POSTPARTUM ONLY; not recommended during pregnancy or breastfeeding (animal data + limited human data)
10. bromocriptine 2.5 mg PO BID × 2 weeks then 2.5 mg PO daily × 6 weeks (8 weeks total) PO BID then daily (dopamine_d2_agonist_prolactin_inhibitor, add on) — IPAC RCT (Sliwa 2017 PMID 28637825): bromocriptine 8-week regimen improved LVEF recovery from 27→58% at 6 mo; POSTPARTUM ONLY (suppresses lactation); add prophylactic AC during therapy due to thrombosis risk
11. enoxaparin 1 mg/kg SC q12h (therapeutic) OR 40 mg SC daily (prophylactic) SC q12h or daily (lmwh, comorbidity specific) — LMWH preferred peripartum (warfarin teratogenic 6-12 weeks gestation + fetal bleeding third trimester); ESC pregnancy 2018 PMID 30165544; therapeutic for AC indication, prophylactic during bromocriptine
12. warfarin 5 mg PO daily; INR target 2-3 PO daily (vitamin_k_antagonist, comorbidity specific) — POSTPARTUM transition from LMWH; safe in lactation (no significant breast milk transfer)
13. apixaban 5 mg PO BID PO BID (doac_factor_xa_direct, comorbidity specific) — POSTPARTUM alternative to warfarin; NOT recommended during breastfeeding (limited data); preferred for AF or LV thrombus per AHA 2022

Setting playbook (outpatient) — Long-term PPCM surveillance: serial LVEF at 3 mo + 6 mo + 12 mo; ICD eligibility re-evaluation if LVEF <35% at 3-6 mo on full GDMT; future-pregnancy counseling; cross-link to chronic HF if no recovery
14. continue 4-pillar GDMT until LVEF normalized + stable ≥6-12 mo ARNI + BB + MRA + SGLT2i at max tolerated PO as scheduled — Persistent HFrEF (ACC/AHA 2022 HF; do not de-escalate prematurely (TRED-HF PMID 30429051 — withdrawal causes deterioration))
15. consider GDMT continuation even after LVEF recovery for at least 12 months maintain PO as scheduled — LVEF recovered but recent (TRED-HF PMID 30429051; AHA 2020 PPCM scientific statement (PMID 32362133) suggests indefinite GDMT in PPCM)

Non-pharmacologic actions:
- Future-pregnancy counseling — recurrence rate 30-50% if LVEF did not normalize; counsel against pregnancy if persistent LV dysfunction
- Reliable contraception — counsel re: progestin-only or IUD (combined oral contraceptives raise thrombosis risk + are not preferred)
- Cardiac rehab maintenance
- ICD/WCD evaluation if LVEF <35% at 3-6 mo on full GDMT
- Family screening if familial CMP suspected

AVOID / contraindication checks:
- Avoid_acei_arb_arni_during_pregnancy_teratogenic (FDA Pregnancy Category D — fetal renal dysgenesis, oligohydramnios, neonatal hypotension)
- Avoid_spironolactone_during_pregnancy (antiandrogenic — feminization of male fetus theoretical)
- Avoid_warfarin_pregnancy_weeks_6_to_12 (warfarin embryopathy — nasal hypoplasia, stippled epiphyses)
- Avoid_warfarin_third_trimester (fetal intracranial hemorrhage at delivery)
- Avoid_sglt2i_during_pregnancy_or_breastfeeding (animal teratogenicity + limited human data)
- Avoid_bromocriptine_during_pregnancy_or_if_breastfeeding_desired (suppresses lactation — counsel patient)
- Add_prophylactic_anticoagulation_during_bromocriptine_therapy (increased thrombosis risk per IPAC)
- Avoid_doac_during_pregnancy_or_breastfeeding (insufficient data)
- Hydralazine_nitrate_substitute_for_acei_during_pregnancy (pregnancy safe afterload + preload reduction; A HeFT analog)
- Metoprolol_succinate_or_carvedilol_safe_in_pregnancy_and_lactation (preferred BB)
- Obstetric_team_must_co_manage_delivery_decision_in_severe_ppcm (vaginal preferred unless obstetric indication; epidural fluid load careful)

Monitoring

Regimen monitoring:
- continuous telemetry for arrhythmia detection (PPCM has elevated VT/VF risk if LVEF <35%)
- daily weight strict io (volume management critical)
- q6 to 12h bmp during diuresis (hypokalemia risk)
- fetal heart monitoring if antepartum (continuous if SBP <100 or on inotrope)
- echo at 1 week then 6 weeks then 3 months then 6 months postpartum (LVEF recovery trajectory)
- lactation consult if bromocriptine planned (irreversible lactation suppression)
- inr q week during warfarin titration postpartum (target 2-3)
- anti xa monitoring during lmwh in pregnancy (target 0.6-1.0 U/mL therapeutic)

Setting (outpatient) monitoring:
- Quarterly clinic visits + echo
- Annual BNP/NT-proBNP
- INR if on warfarin

Follow-up plan: PPCM clinic at 2 weeks, 6 weeks, 3 months, 6 months postpartum; serial echo for LVEF recovery; future-pregnancy counseling (recurrence 30-50% if LVEF did not normalize); ICD/WCD evaluation if LVEF still <35% at 3-6 months on full GDMT
- Close-out criterion: PPCM clinic + future-pregnancy counseling + ICD pathway documented

Monitoring phase: Continuous telemetry, daily weight, hourly UOP, fetal monitoring if antepartum, daily BMP, repeat echo at 1 week and at 6 weeks postpartum for LVEF recovery trajectory

Disposition

Current setting: outpatient — Long-term PPCM surveillance: serial LVEF at 3 mo + 6 mo + 12 mo; ICD eligibility re-evaluation if LVEF <35% at 3-6 mo on full GDMT; future-pregnancy counseling; cross-link to chronic HF if no recovery

Disposition criteria:
- Long-term continuation; cross-link to cardio.hfref.core.v1 if HFrEF persists past 12 mo

Escalation triggers (move to higher acuity):
- New pregnancy in patient with persistent LV dysfunction → urgent MFM + cardiology + advanced HF eval
- Worsening LVEF despite GDMT → advanced HF + transplant evaluation
- ICD therapy delivered → urgent EP

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Fulminant PPCM with cardiogenic shock peripartum (SBP <90, lactate ≥4, SCAI C-E) — very high maternal + fetal mortality
- [LIFE_THREATENING] PPCM patient on therapeutic LMWH with peripartum bleeding (placental abruption, postpartum hemorrhage, intracranial hemorrhage)
- [SEVERE] Patient with prior PPCM + LVEF that did not normalize + new pregnancy — recurrence rate 30-50%, mortality up to 20%

Citations

- AHA 2020 PPCM Scientific Statement + ESC pregnancy 2018 + 2022 ACC/AHA HF + IPAC RCT 2017 [PMID:28637825](https://pubmed.ncbi.nlm.nih.gov/28637825/)
- Cited evidence (PMID 30165544) [PMID:30165544](https://pubmed.ncbi.nlm.nih.gov/30165544/)
- Cited evidence (PMID 32362133) [PMID:32362133](https://pubmed.ncbi.nlm.nih.gov/32362133/)
- Cited evidence (PMID 28612476) [PMID:28612476](https://pubmed.ncbi.nlm.nih.gov/28612476/)
- Cited evidence (PMID 17320504) [PMID:17320504](https://pubmed.ncbi.nlm.nih.gov/17320504/)

Last reconciled with current guidelines: 2026-05-15.
References